Back to search results

AchromoPhage for Achromobacter Lung Infection in Cystic Fibrosis

This study is testing a new treatment called AchromoPhage for adults with cystic fibrosis (CF) who have long-term lung infections caused by Achromobacter bacteria. AchromoPhage is a mixture of four natural viruses, called bacteriophages, that are designed to target and kill Achromobacter. The main goal of this study is to see if AchromoPhage is safe and well tolerated. This study plans to enroll 12 participants who are 18 years or older, weigh at least 40 kg, and have stable breathing symptoms. Participants will receive AchromoPhage in different ways: by breathing it in (inhalation), through a vein (intravenous or IV infusion), or both. The study will measure any serious side effects within 42 days.

Study design
This is an open-label, randomized pilot and feasibility study involving 12 participants. Participants will be assigned to one of three groups to receive AchromoPhage.
What's involved
You will receive the study drug during clinic visits over a period of three weeks. Each participant will receive three weekly administrations with increasing doses.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint for safety is measured at 42 days after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07275905

Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection

Recruiting
PHASE1Ages 18+InterventionalTreatment
Ghady Haidar
~12 participants
Updated 2026-07-15 on ClinicalTrials.gov
What's tested:AchromoPhage

At a glance

Recruiting sites
1 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of treatment-related Grade ≥4 adverse events or treatment-limiting toxicities
Measured over 42 Days

Conditions

Cystic Fibrosis (CF)
Achromobacter Infection

Explore related trials

Cystic FibrosisInfection caused by Cronobacter

Where it's being run

2 sites across 2 states
California1
Pennsylvania1

Study leadership

  • Ghady Haidar, MD · PRINCIPAL_INVESTIGATOR · University of Pittsburgh

Who to contact

Breuna N Bishop - Program Manager, Pittsburgh Phage Program, MSE
[email protected]
412-368-6380
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

Exclusion

An individual who meets any of the following criteria will be excluded from participation in this study:

What this trial measures

  • Incidence of treatment-related Grade ≥4 adverse events or treatment-limiting toxicities42 Days

    Incidence of treatment-related Grade 4 or higher adverse events or any treatment-limiting toxicities, assessed overall and by treatment group, from the first dose through Day 42. Severity grading will follow the protocol-specified adverse event definitions.